Stocks Health care PMCB
NASDAQ · Health carePharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. brought in $0 of revenue over the twelve months to July 31, 2026. It posted a net loss of $16.1M. At July 31, 2026 it held $17.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 14, 2026.
Key facts about PharmaCyte Biotech, Inc.
- Net worth
- PharmaCyte Biotech, Inc. has a market value (market cap) of $4.3M at the latest share price, and shareholders' equity of $27.5M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $0, with a net loss of $19.4M. Over the 12 months to July 31, 2026: revenue $0, net loss $16.1M.
- Cash flow
- In fiscal 2026 operations used $5.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 14, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR
- Next earnings report
- PharmaCyte Biotech, Inc.'s next report is expected around December 17, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What PharmaCyte Biotech, Inc. does
PharmaCyte Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PMCB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $0 | -$19.4M | -$2.77 | n/a |
| 2025 | $0 | $30.7M | $3.19 | n/a |
| 2024 | $0 | $333.8K | -$1.80 | n/a |
| 2023 | $0 | -$4.3M | -$0.22 | n/a |
| 2022 | $0 | -$4.2M | -$0.27 | n/a |
| 2021 | $0 | -$3.6M | -$2.45 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What PharmaCyte Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- July 29, 2026
- April 2, 2026
- March 17, 2026
- March 9, 2026
- March 9, 2026Proxy statement DEF 14A
- February 27, 2026Preliminary proxy statement PRE 14A
- February 13, 2026Passive stake changed SCHEDULE 13G/A
- December 18, 2025
- December 15, 2025Late quarterly report notice NT 10-Q
Insider trades
What the people running PharmaCyte Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 7, 2026 | Schechter JonathanDirector | Bought | 20,000 | $16.9K |
| January 7, 2026 | Silverman JoshuaCEO and President, Director | Bought | 40,000 | $33.3K |
| January 6, 2026 | Schechter JonathanDirector | Bought | 20,000 | $15.8K |
| January 6, 2026 | Silverman JoshuaCEO and President, Director | Bought | 30,000 | $23.7K |
| January 5, 2026 | Schechter JonathanDirector | Bought | 20,000 | $15.6K |
| January 5, 2026 | Silverman JoshuaCEO and President, Director | Bought | 30,000 | $23.5K |
| December 12, 2025 | Abecassis Michael MDirector | Received as pay | 37,500 | - |
| December 12, 2025 | Abecassis Michael MDirector | Shares withheld for tax | 16,875 | $17.2K |
Who owns PMCB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ayrton Capital LLC13G, passive with 2 related filers | 9.9% | February 13, 2025 |
Largest institutional holders
Insiders
5 insiders reported holding 692,917 shares in total, about $278.6K at the last price.
| Holder | Shares |
|---|---|
| Silverman JoshuaCEO and President, Director | 416,250 |
| Schechter JonathanDirector | 192,500 |
| Weinstein RobertDirector | 41,250 |
| Abecassis Michael MDirector | 22,292 |
| Walker Wayne RemellDirector | 20,625 |
Questions about PMCB
What does PharmaCyte Biotech, Inc. do?
PharmaCyte Biotech, Inc. is a company in the Health care sector, listed on NASDAQ as PMCB. Its shares trade on NASDAQ under the ticker PMCB.
What is PharmaCyte Biotech, Inc.'s net worth?
PharmaCyte Biotech, Inc. has a market value (market cap) of $4.3M at the latest share price, and shareholders' equity of $27.5M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is PharmaCyte Biotech, Inc. profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $16.1M.
How much revenue does PharmaCyte Biotech, Inc. make?
Over the twelve months to July 31, 2026 PharmaCyte Biotech, Inc. reported revenue of $0.
When did PharmaCyte Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 14, 2026. It covers the period to July 31, 2026.
When is PharmaCyte Biotech, Inc.'s next earnings report?
PharmaCyte Biotech, Inc.'s next report is expected around December 17, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PMCB with
Follow PMCB
Get an email when PharmaCyte Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values PharmaCyte Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.